• There are a number of available treatments for insomnia which in clinical studies have demonstrated significant improvements in sleep latency, sleep time, sleep quality, daytime ability to function and physical well-being. [4] [5] [6] • However, these medications are associated with a variety of unwanted effects including both cognitive and psychomotor adverse events. [7] [8] It remains unclear the extent to which the health outcomes of patients are restored (relative to those without insomnia) upon being treated for insomnia. 
OBJECTIVES
• To quantify the burden of insomnia (based on DSM-V criteria) with respect to health outcomes, including health status, work productivity, and healthcare resource use in the United States (US) and Western Europe (5EU; France, Germany, Italy, Spain and UK).
• To quantify the morbidity of treated insomnia (based on DSM-V criteria) with respect to health outcomes, including health status, work productivity and healthcare resource use in the US and 5EU.
• To estimate the prevalence of non-adherence to insomnia medications due to tolerability issues and the association between these tolerability issues and health outcomes, including health status, work productivity and healthcare resource use in the US and 5EU.
METHODS

Data Source
• The 2013 US (N=75,000) and 2013 5EU (N=62,000) National Health and Wellness Survey (NHWS) datasets were used for this study. The NHWS is a patient-reported survey administered to a demographically representative sample of adults (with respect to age, sex, race/ethnicity and region).
• The NHWS is a cross-sectional, Internet survey given to a sample of adults (18 years and older) who were identified through a web-based panel. Invitations to participate in the NHWS were sent using a random stratified sampling framework to ensure the final sample of NHWS participants is representative of the adult population in each of the participating countries.
Measures
• Insomnia, treated insomnia and tolerability issues. All respondents were classified into an insomnia group or a control group based on DSM-V criteria.
o Those who met criteria for the insomnia group definition and were using a prescription medication were considered part of the "treated insomnia" group.
o Among those in the treated insomnia group, those who reported they stopped taking their insomnia medication because they felt worse were considered to be experiencing tolerability issues. Those who were in the treated group but did not endorse that item were considered not to have tolerability issues.
• Sociodemographics and health history. Age, race/ethnicity (in the US only), gender, marital status, education, annual household income, body mass index (BMI), alcohol consumption, exercise behaviour, smoking status and the Charlson comorbidity index (CCI) were assessed.
• Health status. The Short Form 36 version 2 (SF-36v2) was used to assess health status. The SF-36v2 items are used to calculate two summary scores (mental [MCS] and physical component summary [PCS] scores) which are normed to the general population (Mean = 50; standard deviation [SD] =10) and a preference-based health utility score, which conceptually varies from 0 (death) to 1 (perfect health).
• Work impairment. Work and activity-related impairment was assessed using the general health version of the Work Productivity and Activity Impairment (WPAI) questionnaire. All metrics in the results are presented as percentages of impairment.
• Healthcare resource utilisation. The number of physician visits, emergency room visits and hospitalisations in the past six months were reported by all respondents.
Statistical Analyses
• Analyses were conducted separately in the US and 5EU, though the modelling approach was identical.
• The insomnia group was compared with a propensity score-matched control group with respect to health outcomes using ANOVA tests.
o The matched control group was created by being matched to the insomnia group on demographics, health history and comorbidities.
• The treated insomnia group was also compared with a propensity score-matched control group with respect to health outcomes using ANOVA tests.
o The matched control group was created by being matched to the treated insomnia group on demographics, health history and comorbidities.
• Patients who reported tolerability issues were compared with those without tolerability issues (among those also treated for insomnia) on health outcomes using generalized linear models controlling for demographics, health history and comorbidities.
RESULTS
• In the US, 4,517 (6.0%) met the criteria for the insomnia group compared with 32,442 who met criteria for the control group. In the 5EU, 4,151 (6.7%) met criteria for the insomnia group compared with 27,510 who met criteria for the control group.
• In both regions, those with insomnia were more likely to be female, unmarried, and have lower socioeconomic status (lower education/income), and a poorer health behavioural profile (more likely to smoke and not exercise) (all p<.05).
• Compared with matched controls, patients with insomnia reported significantly worse health status in both the US and 5EU (all p<.05; see Figure 1 ).
• Health utilities were also significantly lower among those with insomnia relative to matched controls (US: 0.62 vs. 0.76, p<.05; 5EU: 0.60 vs. 0.74, p<.05).
Figure 1. Differences between patients with insomnia and matched controls with respect to health status in the US and 5EU
• Similarly, compared with matched controls, patients with insomnia reported significantly greater work and activity impairment along with increased healthcare resource use in the past six months in both regions (all p<.05; see Figures 2-3 ).
• Patients treated for insomnia also reported significantly worse health, greater work impairment, activity impairment, and increased healthcare resource use in the past six months in both regions compared with matched controls (all p<.05; see .
o Health utilities were also significantly lower among those with treated insomnia relative to matched controls (US: 0.63 vs. 0.76, p<.05; 5EU: 0.60 vs. 0.74, p<.05).
• Among those treated for insomnia, 13.56% and 24.55% in the US and 5EU, respectively, were non-adherent due to side effects. In the US, this behaviour was associated with significantly worse health status and significantly greater presenteeism, overall work impairment and activity impairment (all p<.05; see Table 1 ).
o These relationships were not significant in the 5EU. 
LIMITATIONS
• All data were self-reported and no verification of an insomnia diagnosis, treatment usage, or healthcare resource use was available.
• The study was cross-sectional so causality between insomnia, treatments, level of satisfaction and health outcomes is only hypothesised.
• Although the NHWS is demographically representative, it is unclear the extent to which this analytical sample generalises to the various insomnia subpopulations in each country.
CONCLUSIONS
• The results suggest a significant humanistic and economic burden among those with insomnia across both regions, similar to past research [2] [3] .
o Differences between groups were large, with insomnia respondents often reporting more than double the impairment and resource use events relative to matched controls.
• A wide gap in health outcomes remained between treated respondents and matched controls, suggesting that current treatments are still not able to elevate the health outcomes of those with insomnia to similar levels of those without insomnia.
• In part, this gap could be explained by adverse events of the treatments. The presence or absence of specific tolerability issues were not assessed directly in the NHWS, but a total of 13.6% in the US and 24.6% in 5EU reported not taking their insomnia medication due to tolerability issues (suggesting rates of actual tolerability issues would be higher). 
